matrix™
GEL•SYSTEM

MATRIX™ ERYGEN - ABO	102070032	3 x 2 ml
MATRIX™ ERYGEN - A_1	102020010	10 ml
MATRIX™ ERYGEN - B	102030010	10 ml
MATRIX™ ERYGEN - O	102040010	10 ml

MATRIX™ ERYGEN - ABO
0.8% Reagent Red Blood Cells for Reverse Grouping

SUMMARY
In the ABO system, human red blood cell antigens can be divided into four groups A, B, AB and O depending on the presence or absence of the corresponding antigens on the red blood cells. Agglutination tests of red blood cells using the Anti-A and Anti-B reagents, is known as forward grouping. Forward grouping can be confirmed by testing the patient's serum/plasma using red cells of known ABO group to demonstrate the presence/absence of Anti-A and/or Anti-B, the results of which determines the reverse group. **MATRIX™ ERYGEN - ABO** are reagent red cell for reverse grouping.

REAGENTS
MATRIX™ ERYGEN - ABO is a reagent for laboratory use only.
MATRIX™ ERYGEN - ABO 0.8% reagent red blood cells comprise of:
1. Red Blood Cells of Group A_1.
2. Red Blood Cells of Group B.
3. Red Blood Cells of Group O.

The reagent red blood cells are suspended in isotonic medium to which a Red Cell Preserving solution is added to preserve the red cell integrity and antigenicity.

STORAGE AND STABILITY
Store at 2-8 ^{0}C. Do not freeze. The usage is limited by the expiry date on the vial label. The reactivity of the cells may decrease during the shelf life due to the physiological ageing process.

ADDITIONAL REAGENTS AND MATERIALS REQUIRED
Test cards and equipment for the appropriate antibody detection system.
Dispenser, pipettes, gel card centrifuge.

SAMPLE COLLECTION
No special preparation of the patient is required prior to sample collection by approved techniques. For optimal results, freshly collected samples should be used. Anticoagulants like EDTA, CPD-A and Citrate can be used. Serum or plasma samples can be used. Samples should be centrifuged at 1500g for 10 minutes to avoid fibrin residue which may interfere with results.

NOTE
1. In vitro diagnostic reagent only.
2. **MATRIX™ ERYGEN - ABO** should not be pooled or transferred into another container.
3. Do not use hemolysed, lipemic and icteric samples.
4. Each donor unit was nonreactive for HBsAg, anti-HCV, anti-HIV1+2 when tested with licensed reagents. No test method can assure that products of human source will not transmit the causative organism. Products from human blood should be considered potentially infectious.
5. Positive and negative controls should be included as recommended by national guidelines/GLP.

APPLICATION OF MATRIX™ ERYGEN - ABO
Strictly follow the manufacturer instructions for use for test procedure.
Gently resuspend the cells by inverting the vial several times (10-20 times). Red cells should be well suspended and bring at room temperature before use. To prevent contamination avoid changing of vial pipettes.

INTERPRETATION OF RESULTS
No agglutination indicates: No antibody against any corresponding red cell antigen is detectable.
Agglutination indicates: Antibodies against corresponding ABO antigens are detectable.
Hemolysis : Indicate antigen/antibody reaction.

REFERENCES

(1) AABB, Technical Manual, 16th Edition, American Association of Blood Banks, 2008. (2) Harvey G. Klein and D. J. Anstee: Mollison's Blood transfusion in Clinical Medicine, 11th Edition, Blackwell Publishing, 2005. (3) P.D. Issitt and D. J. Anstee: Applied Blood Group serology, 4th Edition, Montgomery scientific Publications, 1988. (4) Data on file: Tulip Diagnostics (P) Ltd.

Manufactured by:
TULIP DIAGNOSTICS (P) LTD.
Plot Nos. 92/96, Phase II C, Verna Industrial Estate,
Verna Goa - 403 722 India
Website: www.tulipgroup.com

10207/0217/AE/VER-1